Regenerative Medical Technology RMTG
OTC RMTG
$0.03 +0.00 (+0.00%)
At close: Nov 10, 2026 · 4:00 PM EST

Regenerative Medical Technology (RMTG) Income from Discontinued Operations (2022 - 2023)

Updated

Analysis

Regenerative Medical Technology (RMTG) Income from Discontinued Operations (2022 - 2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Discontinued) (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Regenerative Medical Technology 412,169.03 -4.11 Mn 2.58 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 -67,963.00
Mar 31, 2023 124.00
Dec 31, 2022 68,663.00
Sep 30, 2022 -434.00
Jun 30, 2022 208.00
Mar 31, 2022 -124.00
API Access

Regenerative Medical Technology Income from Discontinued Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-discontinued-operations&ticker=RMTG&period=max&api_key=YOUR_API_KEY